Pfizer (PFE) Stock Forecast & Price Target

Compare

199 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PFE Analyst Ratings

Moderate Buy

6 Buy

13 Hold

0 Sell

Based on 19 analysts giving stock ratings to

Pfizer

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PFE Stock 12 Month Forecast

Average Price Target

€24.33

▲(3.38% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for Pfizer in the last 3 months. The average price target is €24.33 with a high forecast of €29.94 and a low forecast of €21.11. The average price target represents a 3.38% change from the last price of €23.53.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"18":"€18","21":"€21","24":"€24","27":"€27","30":"€30"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":29.9406506454,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€29.94</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.3257232119,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€24.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.10874975,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€21.11</span>\n  </div></div>","useHTML":true}}],"tickPositions":[18,21,24,27,30],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.445,23.021588511184614,23.59817702236923,24.174765533553845,24.751354044738463,25.327942555923077,25.904531067107694,26.481119578292308,27.057708089476925,27.63429660066154,28.210885111846157,28.78747362303077,29.364062134215388,{"y":29.9406506454,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.445,22.5896710163,22.7343420326,22.8790130489,23.0236840652,23.1683550815,23.3130260978,23.4576971141,23.602368130400002,23.7470391467,23.891710163000003,24.0363811793,24.181052195600003,{"y":24.3257232119,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.445,22.34221151923077,22.23942303846154,22.136634557692307,22.033846076923076,21.931057596153845,21.828269115384614,21.725480634615387,21.622692153846156,21.519903673076925,21.417115192307694,21.314326711538463,21.211538230769232,{"y":21.10874975,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.93,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.268,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.552,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.944,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.485,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 57, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.274,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.469,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.484,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.234,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.545,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.92,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.445,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€29.94

Average Price Target€24.33

Lowest Price Target€21.11

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Narumi Nakagiri

Daiwa

€22.75

Hold

-3.30%

Downside

Downgraded

02/12/26

Pfizer downgraded to Neutral from Outperform at DaiwaPfizer downgraded to Neutral from Outperform at Daiwa

Courtney Breen

Bernstein

€25.28

Hold

7.44%

Upside

Reiterated

02/10/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Align Tech (NASDAQ: ALGN), Vertex Pharmaceuticals (NASDAQ: VRTX) and Pfizer (NYSE: PFE)

Vamil Divan

Guggenheim

€29.5

Buy

25.35%

Upside

Reiterated

02/06/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: aTyr Pharma (NASDAQ: ATYR), Pfizer (NYSE: PFE) and Bicycle Therapeutics (NASDAQ: BCYC)

Jill Wu

CMB International Securities

€29.88

Buy

27.00%

Upside

Reiterated

02/05/26

Analysts' Top Healthcare Picks: Coherus Biosciences (CHRS), Pfizer (PFE)

Jason Gerberry

Bank of America Securities

€22.75

Hold

-3.30%

Downside

Reiterated

02/04/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN), Pfizer (NYSE: PFE) and Merck & Company (NYSE: MRK)

Geoff Meacham

Citi

€21.91

Hold

-6.88%

Downside

Reiterated

02/04/26

Balanced Near-Term Pipeline Upside Versus Structural Profit Headwinds Keeps Pfizer at Hold

Asad Haider

Goldman Sachs

€21.91

Hold

-6.88%

Downside

Reiterated

02/04/26

Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT), Pfizer (NYSE: PFE) and Inhibikase Therapeutics (NASDAQ: IKT)

Carter Gould

Cantor Fitzgerald

€22.75

Hold

-3.30%

Downside

Reiterated

02/04/26

Analysts Conflicted on These Healthcare Names: Neuren Pharmaceuticals Limited (Other OTC: NURPF) and Pfizer (NYSE: PFE)

Louise Chen

Scotiabank

€25.28

Buy

7.44%

Upside

Reiterated

02/04/26

Scotiabank Reaffirms Their Buy Rating on Pfizer (PFE)

Terence Flynn

Morgan Stanley

€22.75

Hold

-3.30%

Downside

Reiterated

02/03/26

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE) and Pfizer (NYSE: PFE)

Evan Seigerman

BMO Capital

€25.28

Buy

7.44%

Upside

Reiterated

02/03/26

BMO Capital Reaffirms Their Buy Rating on Pfizer (PFE)

Chris Schott

J.P. Morgan

€25.28

Hold

7.44%

Upside

Reiterated

02/03/26

Analysts Offer Insights on Healthcare Companies: Invivyd (NASDAQ: IVVD) and Pfizer (NYSE: PFE)

Michael Yee

UBS

€20.23→€21.07

Hold

-10.46%

Downside

Reiterated

02/03/26

Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE) and Avidity Biosciences (NASDAQ: RNA)

Kerry Holford

Berenberg Bank

€21.07

Hold

-10.46%

Downside

Reiterated

01/28/26

Analysts Offer Insights on Healthcare Companies: Korro Bio (NASDAQ: KRRO), Pfizer (NYSE: PFE) and Alpha Teknova (NASDAQ: TKNO)

Steve Scala

TD Cowen

€25.28

Hold

7.44%

Upside

Reiterated

12/30/25

TD Cowen Sticks to Their Hold Rating for Pfizer (PFE)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Narumi Nakagiri

Daiwa

€22.75

Hold

-3.30%

Downside

Downgraded

02/12/26

Pfizer downgraded to Neutral from Outperform at DaiwaPfizer downgraded to Neutral from Outperform at Daiwa

Courtney Breen

Bernstein

€25.28

Hold

7.44%

Upside

Reiterated

02/10/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Align Tech (NASDAQ: ALGN), Vertex Pharmaceuticals (NASDAQ: VRTX) and Pfizer (NYSE: PFE)

Vamil Divan

Guggenheim

€29.5

Buy

25.35%

Upside

Reiterated

02/06/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: aTyr Pharma (NASDAQ: ATYR), Pfizer (NYSE: PFE) and Bicycle Therapeutics (NASDAQ: BCYC)

Jill Wu

CMB International Securities

€29.88

Buy

27.00%

Upside

Reiterated

02/05/26

Analysts' Top Healthcare Picks: Coherus Biosciences (CHRS), Pfizer (PFE)

Jason Gerberry

Bank of America Securities

€22.75

Hold

-3.30%

Downside

Reiterated

02/04/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN), Pfizer (NYSE: PFE) and Merck & Company (NYSE: MRK)

Geoff Meacham

Citi

€21.91

Hold

-6.88%

Downside

Reiterated

02/04/26

Balanced Near-Term Pipeline Upside Versus Structural Profit Headwinds Keeps Pfizer at Hold

Asad Haider

Goldman Sachs

€21.91

Hold

-6.88%

Downside

Reiterated

02/04/26

Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT), Pfizer (NYSE: PFE) and Inhibikase Therapeutics (NASDAQ: IKT)

Carter Gould

Cantor Fitzgerald

€22.75

Hold

-3.30%

Downside

Reiterated

02/04/26

Analysts Conflicted on These Healthcare Names: Neuren Pharmaceuticals Limited (Other OTC: NURPF) and Pfizer (NYSE: PFE)

Louise Chen

Scotiabank

€25.28

Buy

7.44%

Upside

Reiterated

02/04/26

Scotiabank Reaffirms Their Buy Rating on Pfizer (PFE)

Terence Flynn

Morgan Stanley

€22.75

Hold

-3.30%

Downside

Reiterated

02/03/26

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE) and Pfizer (NYSE: PFE)

Evan Seigerman

BMO Capital

€25.28

Buy

7.44%

Upside

Reiterated

02/03/26

BMO Capital Reaffirms Their Buy Rating on Pfizer (PFE)

Chris Schott

J.P. Morgan

€25.28

Hold

7.44%

Upside

Reiterated

02/03/26

Analysts Offer Insights on Healthcare Companies: Invivyd (NASDAQ: IVVD) and Pfizer (NYSE: PFE)

Michael Yee

UBS

€20.23→€21.07

Hold

-10.46%

Downside

Reiterated

02/03/26

Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE) and Avidity Biosciences (NASDAQ: RNA)

Kerry Holford

Berenberg Bank

€21.07

Hold

-10.46%

Downside

Reiterated

01/28/26

Analysts Offer Insights on Healthcare Companies: Korro Bio (NASDAQ: KRRO), Pfizer (NYSE: PFE) and Alpha Teknova (NASDAQ: TKNO)

Steve Scala

TD Cowen

€25.28

Hold

7.44%

Upside

Reiterated

12/30/25

TD Cowen Sticks to Their Hold Rating for Pfizer (PFE)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pfizer

3 Months

xxx

Success Rate

25/35 ratings generated profit

Average Return

+3.15%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +3.15% per trade.

1 Year

Vamil DivanGuggenheim

Success Rate

28/35 ratings generated profit

Average Return

+7.35%

reiterated a buy rating 12 days ago

Copying Vamil Divan's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +7.35% per trade.

2 Years

xxx

Success Rate

18/20 ratings generated profit

Average Return

+10.03%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 90.00% of your transactions generating a profit, with an average return of +10.03% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PFE Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PFE has received 20 Buy Ratings, 36 Hold Ratings, and 0 Sell Ratings. PFE average Analyst price target in the past 3 months is 24.33.

Each month's total comprises the sum of three months' worth of ratings.

PFE Financial Forecast

PFE Earnings Forecast

Next quarter’s earnings estimate for PFE is €0.62 with a range of €0.54 to €0.78. The previous quarter’s EPS was €0.56. PFE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year PFE has Performed in-line its overall industry.

PFE Sales Forecast

Next quarter’s sales forecast for PFE is €11.73B with a range of €11.39B to €12.12B. The previous quarter’s sales results were €14.82B. PFE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year PFE has Performed in-line its overall industry.

PFE Stock Forecast FAQ

What is DE:PFE’s average 12-month price target, according to analysts?

Based on analyst ratings, Pfizer’s 12-month average price target is 24.33.

What is DE:PFE’s upside potential, based on the analysts’ average price target?

Pfizer has 3.38% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Pfizer a Buy, Sell or Hold?

Pfizer has a consensus rating of Moderate Buy, which is based on 6 buy ratings, 13 hold ratings and 0 sell ratings.

What is Pfizer’s share price target?

The average share price target for Pfizer is 24.33. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €29.94 ,and the lowest forecast is €21.11. The average share price target represents 3.38% Increase from the current price of €23.53.

What do analysts say about Pfizer?

Pfizer’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of Pfizer?

To buy shares of DE:PFE, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Pfizer (PFE) Stock Forecast & Price Target

PFE Analyst Ratings

PFE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Pfizer

PFE Analyst Recommendation Trends

PFE Financial Forecast

PFE Earnings Forecast

PFE Sales Forecast

PFE Stock Forecast FAQ

Detailed List of Analyst Forecasts